Cortechs.ai | Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI  Imaging and Machine Learning

Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI Imaging and Machine Learning

Cortechs.ai’ abstract titled “Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects” was accepted by ACTRIMS

Lead author and Cortechs.ai Principal Scientist, Weidong Luo, presented our findings at the 2020 ACTRIMS meeting on Friday, February 28th.

Findings

BACKGROUND
Accurate and early diagnosis of Multiple Sclerosis (MS) is critical for patients to start treatments. In MS
patients, there is a high correlation between various atrophy and physical and cognitive impairments. With the recent
advances in image processing and machine learning methods, a better identification of MS patients using magnetic
resonance imaging (MRI) became achievable.
OBJECTIVE
To evaluate the performance of machine learning models for identifying MS subjects and to study feature
importance selected by models.
METHODS
463 MS (102m/361f, age:18-71yo) and 2315 normal subjects’ data (1080m/1235f, age:18-71yo) were used
in this study. T1-weighted MRI scans were processed by NeuroQuant 3.0 (Cortechs.ai Inc, San Diego, USA) to
generate brain volumetric information (including the volume of cerebral white matter (WM) hypo-intensities). Random
Forests algorithm was used for creating machine learning models. Brain structure volume normalized by Intracranial
Volume (ICV) were used as the input. One-third randomly selected data were used for testing while rest for training.
The performance of the models and the importance of the features based on the whole age range data and specific
age range data were evaluated.
RESULTS
For model one (all data), model area under the curve (AUC) is 0.95 and the precision is 93% and 98%;
sensitivity is 100% and 63% for normal and MS subjects respectively. Top five features are cerebral WM Hypo-
intensities, Thalamus and Cerebellar WM, Age and Isthmus Cingulate. For model two (age < 40 years), the model
AUC is 0.94 and the precision is 92% and 92% for normal and MS subjects while sensitivity is 98% and 76% for
normal and MS subjects respectively. Top three features are the same as the model one. Next two features are
cerebral WM and posterior Superior Temporal Sulcus. For model three (age >= 40 years), the AUC is 0.94 and the
precision is 94% and 96%, sensitivity is 100% and 57% for normal and MS subjects respectively. Top five features
Thalamus, Age, Cerebellar WM, Cerebral WM Hypo-intensities, Isthmus Cingulate.
CONCLUSION
Machine learning models showed high classification performance between normal and MS.
Furthermore, models constructed with data from different age ranges selected different key features thus enabled different precision and sensitivity performance for MS classification. This also suggests evolving effects of disease upon brain during progression. These models might be used as MS classifiers to assist clinicians in decision making.

 

Cortechs.ai | Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI  Imaging and Machine Learning

More Resources

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.
Scroll to Top